Orphazyme A/S (ORPH)

$ 18.2
8.15 (+81.09%)
-
Symbol ORPH
Price $ 18.2
Beta 0.813
Volume Avg. 1.34M
Market Cap 0.64B
Shares () -
52 Week Range 4.75-77.77
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -138.24% Strong Sell
ROA -59.01% Strong Sell
Operating Margin -
Debt / Equity 32.55% Neutral
P/E -
P/B 3.71 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst

ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst

Up nearly 90% today, meme stock Orphazyme is trading at sky high volume just one day ahead of an FDA review for its key drug candidate. The post ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst appeared first on InvestorPlac... ...

InvestorPlace
3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021

3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021

These former penny stocks have followed the path of AMC stock this month The post 3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com. ...

PennyStocks
Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally

Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally

Orphazyme A/S's (NASDAQ: ORPH) major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company's shares. What Happened: Orphazyme said on Tuesday it rece... ...

Benzinga
Top-Performing Biotech ETFs of Last Week

Top-Performing Biotech ETFs of Last Week

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week. ...

Zacks Investment Research
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday

Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID-19 Results: After a protracted delay, Gaithersb... ...

Benzinga
ORPH Stock Price: Over 20% Increase Pre-Market Details

ORPH Stock Price: Over 20% Increase Pre-Market Details

The stock price of Orphazyme (NASDAQ: ORPH) increased by over 20% pre-market. These are the details. ...

Pulse2
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com. ...

PennyStocks
ORPH Stock Price: Over 50% Decrease Pre-Market Explanation

ORPH Stock Price: Over 50% Decrease Pre-Market Explanation

The stock price of Orphazyme A/S (NASDAQ: ORPH) fell by over 50% pre-market. These are the details. ...

Pulse2
Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?

Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?

Orphazyme A/S (NASDAQ: ORPH) shares skyrocketed over 300% in the regular session on Thursday. What Happened: Shares of the Denmark-based biopharmaceutical firm touched an intraday high of $77.77, running up 1,387%. ...

Benzinga
Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket

Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket

Today, Orphazyme stock is on the move and is trading with extremely heavy volume, as momentum traders drive up the value of this small cap. The post Orphazyme Stock: 7 Things to Know About ORPH as Shares Skyrocket appeared first on InvestorPlace. ...

InvestorPlace

About


Ms. Kim Stratton
Healthcare
Biotechnology
NMS

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.